The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 2

PMID 32867128

Citations 8

Authors

Maria Camara-Quilez

Aida Barreiro-Alonso

Angel Vizoso-Vazquez

Esther Rodriguez-Belmonte

Maria Quindos-Varela

Monica Lamas-Maceiras

Maria Esperanza Cerdan

Affiliations

Soon will be listed here.

Abstract

High mobility group box B (HMGB) proteins are overexpressed in different types of cancers such as epithelial ovarian cancers (EOC). We have determined the first interactome of HMGB1 and HMGB2 in epithelial ovarian cancer (the EOC-HMGB interactome). Libraries from the SKOV-3 cell line and a primary transitional cell carcinoma (TCC) ovarian tumor were tested by the Yeast Two Hybrid (Y2H) approach. The interactome reveals proteins that are related to cancer hallmarks and their expression is altered in EOC. Moreover, some of these proteins have been associated to survival and prognosis of patients. The interaction of MIEN1 and NOP53 with HMGB2 has been validated by co-immunoprecipitation in SKOV-3 and PEO1 cell lines. SKOV-3 cells were treated with different anti-tumoral drugs to evaluate changes in HMGB1, HMGB2, MIEN1 and NOP53 gene expression. Results show that combined treatment of paclitaxel and carboplatin induces a stronger down-regulation of these genes in comparison to individual treatments. Individual treatment with paclitaxel or olaparib up-regulates NOP53, which is expressed at lower levels in EOC than in non-cancerous cells. On the other hand, bevacizumab diminishes the expression of HMGB2 and NOP53. This study also shows that silencing of these genes affects cell-viability after drug exposure. HMGB1 silencing causes loss of response to paclitaxel, whereas silencing of HMGB2 slightly increases sensitivity to olaparib. Silencing of either HMGB1 or HMGB2 increases sensitivity to carboplatin. Lastly, a moderate loss of response to bevacizumab is observed when NOP53 is silenced.

Citing Articles

Comprehensive Analysis of CCAAT/Enhancer Binding Protein Family in Ovarian Cancer.

Tan J, Wang D, Dong W, Nian L, Zhang F, Zhao H Cancer Inform. 2024; 23:11769351241275877.

PMID: 39238655 PMC: 11375656. DOI: 10.1177/11769351241275877.

Endothelial Cell Response in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children.

Kim J, Shimizu C, He M, Wang H, Hoffman H, Tremoulet A Int J Mol Sci. 2023; 24(15).

PMID: 37569694 PMC: 10418493. DOI: 10.3390/ijms241512318.

Structure and Functions of HMGB2 Protein.

Starkova T, Polyanichko A, Tomilin A, Chikhirzhina E Int J Mol Sci. 2023; 24(9).

PMID: 37176041 PMC: 10179549. DOI: 10.3390/ijms24098334.

Thanksgiving to Yeast, the HMGB Proteins History from Yeast to Cancer.

Lamas-Maceiras M, Vizoso-Vazquez A, Barreiro-Alonso A, Camara-Quilez M, Cerdan M Microorganisms. 2023; 11(4).

PMID: 37110415 PMC: 10142021. DOI: 10.3390/microorganisms11040993.

The Comprehensive Role of High Mobility Group Box 1 (HMGB1) Protein in Different Tumors: A Pan-Cancer Analysis.

Guan H, Zhong M, Ma K, Tang C, Wang X, Ouyang M J Inflamm Res. 2023; 16:617-637.

PMID: 36820147 PMC: 9938709. DOI: 10.2147/JIR.S386898.

References

Liu Y, Li G, Liu C, Tang Y, Zhang S . RSF1 regulates the proliferation and paclitaxel resistance via modulating NF-κB signaling pathway in nasopharyngeal carcinoma. J Cancer. 2017; 8(3):354-362. PMC: 5332885. DOI: 10.7150/jca.16720. View

Sastri M, Haushalter K, Panneerselvam M, Chang P, Fridolfsson H, Finley J . A kinase interacting protein (AKIP1) is a key regulator of cardiac stress. Proc Natl Acad Sci U S A. 2013; 110(5):E387-96. PMC: 3562788. DOI: 10.1073/pnas.1221670110. View

Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K . Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer Biol Ther. 2012; 13(1):25-33. DOI: 10.4161/cbt.13.1.18440. View

Shi B, Wang Y, Yin F . MALAT1/miR-124/Capn4 axis regulates proliferation, invasion and EMT in nasopharyngeal carcinoma cells. Cancer Biol Ther. 2017; 18(10):792-800. PMC: 5678686. DOI: 10.1080/15384047.2017.1373214. View

Barreiro-Alonso A, Lamas-Maceiras M, Rodriguez-Belmonte E, Vizoso-Vazquez A, Quindos M, Cerdan M . High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxid Med Cell Longev. 2015; 2016:5845061. PMC: 4670870. DOI: 10.1155/2016/5845061. View

Maeda D, Chen X, Guan B, Nakagawa S, Yano T, Taketani Y . Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. Int J Gynecol Pathol. 2010; 30(1):30-5. PMC: 3052874. DOI: 10.1097/PGP.0b013e3181e9a319. View

Bernardini M, Lee C, Beheshti B, Prasad M, Albert M, Marrano P . High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia. 2005; 7(6):603-13. PMC: 1501280. DOI: 10.1593/neo.04760. View

Huang Y, Dai L, Gaines D, Droz-Rosario R, Lu H, Liu J . BCCIP suppresses tumor initiation but is required for tumor progression. Cancer Res. 2013; 73(23):7122-33. PMC: 3918420. DOI: 10.1158/0008-5472.CAN-13-1766. View

Guerra B, Fischer M, Schaefer S, Issinger O . The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment. J Exp Clin Cancer Res. 2015; 34:125. PMC: 4612421. DOI: 10.1186/s13046-015-0234-6. View

10.

Wu L, Wang X, Guo Y . Long non-coding RNA MALAT1 is upregulated and involved in cell proliferation, migration and apoptosis in ovarian cancer. Exp Ther Med. 2017; 13(6):3055-3060. PMC: 5450566. DOI: 10.3892/etm.2017.4304. View

11.

Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K . Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med. 2011; 17(8):944-51. PMC: 4578312. DOI: 10.1038/nm.2392. View

12.

He W, Sun Z, Liu Z . Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel. Exp Ther Med. 2015; 10(4):1413-1418. PMC: 4577978. DOI: 10.3892/etm.2015.2679. View

13.

Jones D, Lechertier T, Reynolds L, Mitter R, Robinson S, Kirn-Safran C . Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice. Dis Model Mech. 2012; 6(1):115-24. PMC: 3529344. DOI: 10.1242/dmm.009183. View

14.

Yu H, Tigchelaar W, Koonen D, Patel H, de Boer R, van Gilst W . AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes. PLoS One. 2013; 8(11):e80815. PMC: 3827472. DOI: 10.1371/journal.pone.0080815. View

15.

Choi J, Sheu J, Guan B, Jinawath N, Markowski P, Wang T . Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009; 69(4):1407-15. PMC: 2644345. DOI: 10.1158/0008-5472.CAN-08-3602. View

16.

Varma R, Hector S, Clark K, Greco W, Hawthorn L, Pendyala L . Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep. 2005; 14(4):925-32. View

17.

Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H . Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma. 2014; 61(5):579-84. DOI: 10.4149/neo_2014_070. View

18.

Brennan P, Jing J, Ethunandan M, Gorecki D . Dystroglycan complex in cancer. Eur J Surg Oncol. 2004; 30(6):589-92. DOI: 10.1016/j.ejso.2004.03.014. View

19.

Ju L, Zhao C, Ye K, Yang H, Zhang J . Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur Rev Med Pharmacol Sci. 2016; 20(10):1993-2003. View

20.

Sodek K, Ringuette M, Brown T . Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer. 2009; 124(9):2060-70. DOI: 10.1002/ijc.24188. View